Intraperitoneal insulin infusion versus islet transplantation: Comparative study in patients with type 1 diabetes

Transplantation

Volumn 87, Issue 1, 2009, Pages 66-71

  Vantyghem, Marie Christine ^a   Marcelli Tourvieille, Sophie ^a   Fermon, Catherine ^a   Duhamel, Alain ^a   Raverdy, Violetta ^a   Arnalsteen, Laurent ^a   Kerr Conte, Julie ^a   Noel, Christian ^a   Fontaine, Pierre ^a   Pattou, François ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Implantable pump; Islet transplantation; Type 1 diabetes

Indexed keywords

CREATININE; GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ABDOMINAL PAIN; ADULT; ANEMIA; ARTICLE; BODY MASS; CELL TRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE DURATION; DRUG DELIVERY SYSTEM; DYSPNEA; FEMALE; GASTRITIS; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; INTERMETHOD COMPARISON; LEG EDEMA; LIVER HEMATOMA; MALE; METRORRHAGIA; MINIPUMP; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY CYST; PRIORITY JOURNAL; PROTEINURIA; SEX RATIO; SKIN DISEASE; WEIGHT REDUCTION; CLINICAL TRIAL; COMPARATIVE STUDY; FOLLOW UP; INFUSION; METABOLISM; PANCREAS ISLET TRANSPLANTATION;

ADULT; DIABETES MELLITUS, TYPE 1; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, PARENTERAL; INSULIN; ISLETS OF LANGERHANS TRANSPLANTATION; MALE;

EID: 58949083553     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31818bbdab     Document Type: Article

References (36)

1. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and complications Research Group. N Engl J Med 2000; 342: 381.
2. Nathan DM, Lachin J, Cleary P, et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003; 348: 2294.
3. Martin CL, Albers J, Herman WH, et al. DCCT/EDIC Research Group. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 2006; 29: 340.
4. Saudek CD, Selam JL, Pitt HA, et al. A preliminary trial ofthe programmable implantable medication for insulin delivery. N Engl J Med 1989; 321: 574.
5. Broussole C, Jeandidier N, Hanaire-Broutin H. French multicentre experience of implantable insulin pumps. The EVADIAC Study Group. Evaluation of Active Implants in Diabetes Society. Lancet 1994; 343: 514.
6. Jeandidier N, Selam JL, Renard E, et al. Decreased severe hypoglycemia frequency during intraperitoneal insulin infusion using programmable implantable pumps. EVADIAC Study Group. Diabetes Care 1996; 19: 780.
7. Gin H, Renard E, Melki V, et al. EVADIAC Study Group: Combined improvements in implantable pump technology and insulin stability allow safe and effective long-term intraperitoneal insulin delivery in type 1 diabetic patients: The EVADIAC experience. Diabetes Metab 2003; 29: 602.
8. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54: 2060.
9. Froud T, Ricordi C, Baidal DA, et al. Islet transplantation in type 1 diabetes mellitus using cultured islet and steroid free immunosuppres-sion: Miami experience. Am J Transplant 2005; 5: 2037.
10. Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006; 355: 1318.
11. Badet L, Benhamou PY, Wojtusciszyn A, et al. Expectations and strategies regarding islet transplantation: Metabolic data from the GRAGIL 2 trial. Transplantation 2007; 84: 89.
12. Bromberg JS, Kaplan B, Halloran PF, et al. The islet transplant experiment: Time for a reassessment. Am J Transplant 2007; 7: 2217.
13. Vantyghem MC, Hazzan M, Tourvieille S, et al. Selection of diabetic patients for islet transplantation: A single-center experience. Diabetes Metab 2004; 30: 417.
14. Ricordi C, Lacy PE, Finke EH, et al. Automated method for isolation of human pancreatic islets. Diabetes 1988; 37: 413.
15. Kessler L, Passemard, Oberholzer J, et al. Reduction of blood glucose variability in type 1 diabetic patients treated by pancreatic islet transplantation: Interest of continuous glucose monitoring. Diabetes Care 2002; 25: 2256.
16. Hafiz MM, Faradji RN, Froud T, et al. Immunosuppression and procedure-related complications in 26 patients with type 1 diabetes mellitus receiving allogeneic islet cell transplantation. Transplantation 2005; 80: 1718.
17. Brown H, Prescott R. Applied mixed models in medicine. New York, Wiley 1999.
18. Conover WJ, Iman RL. Rank transformations asabridge between parametric and nonparametric statistics. Am Stat 1981; 35: 124.
19. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr 1974; 19: 716.
20. Paty BW, Senior PA, Lakey JR, et al. Assessment of glycemic control after islet transplantation using the continuous glucose monitor in insulin-independent versus insulin-requiring type 1 diabetes subjects. Diabetes Technol Ther 2006; 8: 165.
21. Ryan EA, Shandro T, Green K, et al. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes 2004; 53: 955.
22. Senior PA, Zeman M, Paty BW, et al. Changes in renal function after clinical islet transplantation: Four-year observational study. Am J Transplant 2007; 7: 91.
23. Campbell PM, Senior PA, Salam A, et al. High risk of sensitization after failed islet transplantation. Am J Transplant 2007; 7: 2311.
24. Monnier L, Colette C, Leiter L, et al. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2007; 30: 185.
25. Fiorina P, Folli F, Bertuzzi F, et al. Long-term beneficial effect of islet transplantation on diabetic macro-/microangiopathy in type 1 diabetic kidney-transplanted patients. Diabetes Care 2003; 26: 1129.
26. Del Carro U, Fiorina P, Amadio S, et al. Evaluation of polyneuropathy markers in type 1 diabetic kidney transplant patients and effects of islet transplantation: Neurophysiological and skin biopsy longitudinal analysis. Diabetes Care 2007; 30: 3063.
27. Fung MA, Warnock GL, Ao Z, et al. The effect of medical therapy and islet cell transplantation on diabetic nephropathy: An interim report. Transplantation 2007; 84: 17.
28. Thompson DM, Begg IS, Harris C, et al. Reduced progression of diabetic retinopathy after islet cell transplantation compared with intensive medical therapy. Transplantation 2008; 85: 1400.
29. Kent LA, Gill GV, Williams G. Mortality and outcome of patients with brittle diabetes and recurrent ketoacidosis. Lancet 1994; 344: 778.
30. Gruessner RW, Sutherland DE, Kandaswamy R, et al. Over 500 solitary pancreas transplants in nonuremic patients with brittle diabetes melli-tus. Transplantation 2008; 85: 42.
31. Johnson JA, Kotovych M,Ryan EA, et al. Reduced fear ofhypoglycemia in successful islet transplantation. Diabetes Care 2004; 27: 624.
32. Barshes NR, Vanatta JM, Mote A, et al. Health-related quality of life after pancreatic islet transplantation: A longitudinal study. Transplantation 2005; 79: 1727.
33. Poggioli R, Faradji RN, Ponte G, et al. Quality of life after islet transplantation. Am J Transplant 2006; 6: 371.
34. Toso C, Shapiro AM, Bowker S, et al. Quality of life after islet transplant: Impact of the number of islet infusions and metabolic outcome. Transplantation 2007; 84: 664.
35. Guignard AP, Oberholzer J, Benhamou PY, et al. GRAGIL Group. Cost analysis of human islet transplantation for the treatment of type 1 diabetes in the Swiss-French Consortium GRAGIL. Diabetes Care 2004; 27: 895.
36. Haardt MJ, Selam JL, Slama G, et al. A cost-benefit comparison of intensive diabetes management with implantable pumps versus multiple subcutaneous injections in patients with type I diabetes. Diabetes Care 1994; 17: 847.